Candel’s shares soar on Phase 3 prostate cancer data despite unclear prospects

Can­del Ther­a­peu­tics’ vi­ral im­munother­a­py can­di­date passed a late-stage test in cer­tain pa­tients with prostate can­cer, send­ing its share price $CADL up around 60% even as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.